Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround GameSeeking Alpha • 02/18/26
Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal CancerBusiness Wire • 02/17/26
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?Zacks Investment Research • 02/11/26
Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In ObesitySeeking Alpha • 02/09/26
14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)Seeking Alpha • 02/06/26
FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical NeedBusiness Wire • 02/06/26